Navigation Links
New drug protects against side effects of chemotherapy
Date:1/22/2013

A drug developed at Linkping University in Sweden protects against the side effects of cancer treatments while strengthening the effects on the tumour. An international drug evaluation is now starting up on a larger group of patients.

The results of the studies with the compound, known as calmangafodipir, were published in the latest issue of the cancer journal Translational Oncology with Professor Rolf G. G. Andersson as the main author. The research was initiated on a substance called mangafodipir, which was used as a contrast media in magnetic resonance scans. But pharmacologists at LiU discovered that it also protected healthy cells in connection with cancer treatments.

"We found that the substance could affect the formation of oxygen radicals, which are a cause of side effects in chemotherapy," says Professor Andersson. For example, the number of white blood cells decreases drastically in almost all the patients, which opens the door to infections that could even be fatal.

The researchers began with cell tests, and then went on to mice infected with cancer cells. The mice were treated with chemotherapy and were administered mangafodipir at the same time. Tumour formation decreased while white blood cells were protected. One problem was that a large portion of the manganese in the substance was released; as a consequence, the positive effect subsided. The free manganese can also be poisonous and cause brain damage.

"We remade the substance and replaced a lot of the manganese with calcium. This yielded a more stable complex, which turned out to be even better at protecting cells, thereby increasing the anti-cancer effect," says Professor Andersson. The effect of mangafodipir was confirmed in a smaller study on patients with colon cancer, which was published in Translational Oncology in February 2012.

Jan Olof G. Karlsson is a senior lecturer at Linkping University and a senior researcher at PledPharma AB who is developing the drug, which will be marketed under the brand name PledOx. An international Phase 2 study, involving patients with cancer of the large intestine, has recently been initiated. The results are expected at the end of the year.


'/>"/>

Contact: Rolf G.G. Andersson
rolf.andersson@liu.se
46-070-237-1080
Linkping University
Source:Eurekalert

Related medicine news :

1. Minimal Exercise Protects Senior’s Hearts According to Recent Study Reviewed By Projects for Natural Health Choices Inc.
2. High levels of vitamin D in plasma protects against bladder cancer
3. Aspirin protects against Barretts esophagus
4. Broken heart syndrome protects the heart from adrenaline overload
5. Vitamin E in diet protects against many cancers
6. Voices Against Brain Cancer Responds to a Mother’s Successful Fight Against her Glioblastoma
7. To protect against injuries, young athletes may need to play more just for fun
8. More Focused Radiation Treatment May Work Better Against Brain Tumors
9. Vapor Steam Cleaners Help Protect Puppies Against Canine Parvovirus Disease, Announces 1-800-GO-VAPOR.com
10. Going Online for Info May Reflect a Pro-Active Stance Against Cancer
11. FDA Panel Recommends Against 1st Drug for Chronic Fatigue Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... leading physicians, Paul Yost, will begin serving as new board chair for Orange ... month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, ...
(Date:3/28/2017)... MA (PRWEB) , ... March 28, 2017 , ... ... for direct measurement of corrosive ions found in power plant water and steam. ... components such as turbines and boilers, leading to extensive maintenance and unplanned shutdowns. ...
(Date:3/28/2017)... ... 2017 , ... A minimally invasive porcelain veneer is increasing ... Association of Dental Laboratories (NADL) is informing dentists about the benefits of minimally ... dental laboratories and technicians that create these veneers. , According to National ...
(Date:3/28/2017)... NJ (PRWEB) , ... March 28, 2017 , ... ... Camp Association’s Tri-State Camp Conference in Atlantic City March 13-16, was a busy ... their team of professional staff discussed strategies for preventing outbreaks among camp communities ...
(Date:3/28/2017)... ... ... Thank you to all who attended Capio Partners Winter 2017 Healthcare Leadership Symposium ... providers and offered an opportunity to collaborate and network with healthcare colleagues across the ... attendees gathered for a lively discussion on trends and issues that healthcare leaders will ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... March 28, 2017 RXi Pharmaceuticals Corporation ... therapeutics that address significant unmet medical needs, today ... the Japan Patent Office (JPO) for the composition ... factor (CTGF) for the treatment or prevention of ... fibrosis and proliferative retinopathy (Japanese Patent #: 6060071).  ...
(Date:3/28/2017)... 2017 The global flow ... billion by 2025, according to a new study by ... diseases and cancer is expected to upsurge the demand ... the coming years. In addition, higher number of physicians ... stem cell therapy, due to adverse effects caused by ...
(Date:3/28/2017)... Elysium Health joins major pharmaceutical companies to ... Cambridge academic scientists through ... Institute today announces Elysium Health as a partner to the ... collaborative projects with academic researchers in Cambridge ... major research investment outside the U.S. for the ...
Breaking Medicine Technology: